Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810287777> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2810287777 abstract "Introduction MAPK and ARF-MDM2-p53 pathways are critical in cutaneous melanomas. This study examined the combination treatment of MEK inhibitor, trametinib, with MDM2 inhibitors, nutlin-3/RG7388/HDM201, in BRAFV600E mutant and p53 wild-type (p53WT) melanoma cell lines and explored the mechanistic basis of these responses. Material and methods Two BRAFV600E and p53WT melanoma cell lines, A375 and WM35, were treated with either trametinib or MDM2 inhibitors, or combinations. Results and discussions The combination treatment in both A375 and WM35 showed additive to synergistic effects by Chou-Talalay median effect analysis and combination index scores. The combination treatments induced higher levels of p53 target gene transcripts (CDKN1A(p21), MDM2, BAX, BBC3(PUMA), TP53I3(PIG-3)) and protein products (p21, MDM2), resulting in increased cell cycle arrest and apoptosis compared with MDM2 inhibitors alone, suggesting trametinib synergized with MDM2 inhibitors via upregulation of p53-dependent pathways. In addition, DUSP6 phosphatase mRNA and protein were down-regulated following pERK reduction by trametinib, but did not change after p53 activation by MDM2 inhibitors. Furthermore, suppression of DUSP6 by siRNA, or inhibition with the small molecule inhibitor, BCI, potentiated the effect of MDM2 inhibitors through increased ATM-dependent p53 phosphorylation, as demonstrated by complete reversal with the ATM inhibitor, KU55933. Conclusion Trametinib synergizes with MDM2 inhibitors through a DUSP6 mechanism in BRAFV600E and p53WT melanoma cells. DUSP6 regulation of p53 phosphorylation via ATM, could be a therapeutic target for combination with treatments involving activation of the ATM/p53 pathway." @default.
- W2810287777 created "2018-07-10" @default.
- W2810287777 creator A5005245931 @default.
- W2810287777 creator A5009598734 @default.
- W2810287777 creator A5035838280 @default.
- W2810287777 creator A5044754179 @default.
- W2810287777 creator A5045811910 @default.
- W2810287777 creator A5090916333 @default.
- W2810287777 date "2018-06-01" @default.
- W2810287777 modified "2023-10-18" @default.
- W2810287777 title "PO-450 MEK inhibition synergizes with MDM2 inhibitors through DUSP6 suppression" @default.
- W2810287777 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.471" @default.
- W2810287777 hasPublicationYear "2018" @default.
- W2810287777 type Work @default.
- W2810287777 sameAs 2810287777 @default.
- W2810287777 citedByCount "0" @default.
- W2810287777 crossrefType "journal-article" @default.
- W2810287777 hasAuthorship W2810287777A5005245931 @default.
- W2810287777 hasAuthorship W2810287777A5009598734 @default.
- W2810287777 hasAuthorship W2810287777A5035838280 @default.
- W2810287777 hasAuthorship W2810287777A5044754179 @default.
- W2810287777 hasAuthorship W2810287777A5045811910 @default.
- W2810287777 hasAuthorship W2810287777A5090916333 @default.
- W2810287777 hasBestOaLocation W28102877771 @default.
- W2810287777 hasConcept C11960822 @default.
- W2810287777 hasConcept C178666793 @default.
- W2810287777 hasConcept C185592680 @default.
- W2810287777 hasConcept C190283241 @default.
- W2810287777 hasConcept C2776192174 @default.
- W2810287777 hasConcept C2777658100 @default.
- W2810287777 hasConcept C2778472372 @default.
- W2810287777 hasConcept C2781249067 @default.
- W2810287777 hasConcept C389152 @default.
- W2810287777 hasConcept C502942594 @default.
- W2810287777 hasConcept C55493867 @default.
- W2810287777 hasConcept C57074206 @default.
- W2810287777 hasConcept C86803240 @default.
- W2810287777 hasConcept C97920573 @default.
- W2810287777 hasConcept C98274493 @default.
- W2810287777 hasConceptScore W2810287777C11960822 @default.
- W2810287777 hasConceptScore W2810287777C178666793 @default.
- W2810287777 hasConceptScore W2810287777C185592680 @default.
- W2810287777 hasConceptScore W2810287777C190283241 @default.
- W2810287777 hasConceptScore W2810287777C2776192174 @default.
- W2810287777 hasConceptScore W2810287777C2777658100 @default.
- W2810287777 hasConceptScore W2810287777C2778472372 @default.
- W2810287777 hasConceptScore W2810287777C2781249067 @default.
- W2810287777 hasConceptScore W2810287777C389152 @default.
- W2810287777 hasConceptScore W2810287777C502942594 @default.
- W2810287777 hasConceptScore W2810287777C55493867 @default.
- W2810287777 hasConceptScore W2810287777C57074206 @default.
- W2810287777 hasConceptScore W2810287777C86803240 @default.
- W2810287777 hasConceptScore W2810287777C97920573 @default.
- W2810287777 hasConceptScore W2810287777C98274493 @default.
- W2810287777 hasLocation W28102877771 @default.
- W2810287777 hasOpenAccess W2810287777 @default.
- W2810287777 hasPrimaryLocation W28102877771 @default.
- W2810287777 hasRelatedWork W1565657149 @default.
- W2810287777 hasRelatedWork W2006228362 @default.
- W2810287777 hasRelatedWork W2010751751 @default.
- W2810287777 hasRelatedWork W2058146945 @default.
- W2810287777 hasRelatedWork W2269849734 @default.
- W2810287777 hasRelatedWork W2317436134 @default.
- W2810287777 hasRelatedWork W2407459131 @default.
- W2810287777 hasRelatedWork W2553716301 @default.
- W2810287777 hasRelatedWork W2573582767 @default.
- W2810287777 hasRelatedWork W2574845375 @default.
- W2810287777 hasRelatedWork W2611566504 @default.
- W2810287777 hasRelatedWork W2742021580 @default.
- W2810287777 hasRelatedWork W2775825721 @default.
- W2810287777 hasRelatedWork W2883970969 @default.
- W2810287777 hasRelatedWork W2905409417 @default.
- W2810287777 hasRelatedWork W2941500297 @default.
- W2810287777 hasRelatedWork W2954815160 @default.
- W2810287777 hasRelatedWork W2972156192 @default.
- W2810287777 hasRelatedWork W3189856459 @default.
- W2810287777 hasRelatedWork W3213793092 @default.
- W2810287777 isParatext "false" @default.
- W2810287777 isRetracted "false" @default.
- W2810287777 magId "2810287777" @default.
- W2810287777 workType "article" @default.